PROPERTY, PLANT AND EQUIPMENT 8 production activity, as well as on their regulatory compliance with Product reliability is control led throughout the development Good Clinical Practices and Good Manufacturing Practices, as process for the drug candidate, and the Company undertakes to described in European and U.S. regulations. maintain the highest standards quality. To this end, the Company performs audits of candidate CMOs The corollary of these commitments is transparency, particularly with a view to assessing the compliance of their practices and with regard to patients. Publication of scientific and especially systems; audits are also carried out of selected CMOs at a clinical data is a practice shared by al l players in the industry, frequency determined during the lifetime of the partnership. particularly through presentations during specialized conferences, publication on dedicated sites and articles in peer- Actions taken to prevent corruption reviewed journals. The Company has carried out an inventory of the geographical location of its main suppliers in order to determine the percentage 8.2.4 NOTE ON METHODOLOGY of its service providers located in countries for which the Corruption Perceptions Index, or CPI, score is above 60. Specific points by indicator This inventory reviewed at 20 suppliers, representing 73% of Greenhouse gas: emissions due to energy consumption of the payments made by the Company in 2017. It indicated that all buildings, employee travel and annual consumption/recharging these suppliers (100%) are located in countries for which the CPI of gas coolants used in refrigeration and climate-control groups. score is above 60. Total personnel: al l registered employees at the end of the Steps taken to ensure consumer health and safety fiscal year, regardless of type of employment contract (excluding None of the Company’s drug candidates is currently on the interns, temporary employees and subcontractors). market or has been granted marketing authorization. Those that Total entering/departing: total number of employees entering/ are furthest advanced are being tested in humans in the context departing the Company during the year. The eligible population of clinical trials that are governed by stringent states regulations. applies to the “total personnel” indicator. Human rights Number of accidents: any accident occurring suddenly due to the GenSight Biologics is developing drugs that may be able to treat fact or occasion of the work and giving rise to official justification diseases with a high medical need. The Company undertakes to is recorded as a work accident. respect patients participating in its clinical trials. Rate of absenteeism: the number of days of absences over Our practices aiming to produce reliable, pertinent and traceable the theoretical number of days worked. Included are sick leave, data are controlled through our quality system, which draws on absences due to occupational accidents, absences for personal everything from exploratory research to clinical development. projects. Grenelle II Concordance Table Information required by Article R.225-105-1 of the French Commercial Code Registration Document Comment Employment The total workforce and breakdown of employees by gender, age and Section 17.2 geographic area New hires and redundancies Section 17.2 Remuneration and changes in remuneration Section 17.2 Organization of work Organization of working hours Section 17.2 Absenteeism Section 17.2 Health and safety Workplace health and safety conditions Section 17.2 Workplace accidents, specifically their frequency and severity, and Section 17.2 occupational illnesses GENSIGHT BIOLOGICS – 2017 Registration Document– 105